Metrics as of 10/14/2026, 06:23 PM (Berlin time), refresh in progress.
Recursion Pharmaceuticals Stock
Recursion Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Najat Khan
- Employees
- 600
- Market cap
- $1.9 B
- IPO
- 16/04/2021
Recursion Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector headquartered in Salt Lake City, US. Founded in 2013, the company is currently in its clinical development phase and aims to revolutionize drug discovery by decoding biological processes through an integrated approach combining…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Recursion Pharmaceuticals stock: price history
1D
-4.0%
1W
-13.7%
1M
+8.1%
6M
-1.7%
YTD
-9.9%
1Y
-37.4%
2Y
-45.2%
5Y
-80.6%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~41% stronger price swings than usual
Ask the agents about Recursion Pharmaceuticals
Analyst assessment of Recursion Pharmaceuticals
PRICE TARGET LOW
US$5.30
CONSENSUS
US$5.30
MEDIAN
US$5.30
PRICE TARGET HIGH
US$5.30
0
STRONG BUY
4
BUY
6
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Hold
As of: 14/05/2026
Recursion Pharmaceuticals stock metrics
P/E
-3.55
P/B
2.15
EV/EBITDA
-3.27
RETURN ON EQUITY
-14.3%
NET MARGIN
-1,708.0%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.9%
FLOAT SHARES
408,726,785
AVG. DAILY VOLUME (30D)
25,297,054
Insider transactions (SEC)
Borgeson Blake
HERSHBERG ROBERT
HERSHBERG ROBERT
Dar Zavain
Li Dean Y
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Recursion Pharmaceuticals stock
What does Recursion Pharmaceuticals do?
Recursion Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Najat Khan, the company employs around 600 people.
The IPO was on 16/04/2021; the stock trades on NASDAQ under the ticker RXRX.
What do analysts say about Recursion Pharmaceuticals stock?
10 analysts rate the stock, the consensus is Hold (as of 14/05/2026).
The average price target is US$5.30, ranging from US$5.30 to US$5.30, with a median of US$5.30.
This is an external assessment, not a statement by Market Jury.
When does Recursion Pharmaceuticals report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 41% stronger than usual.
Does Recursion Pharmaceuticals pay a dividend?
No, Recursion Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Recursion Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Recursion Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Recursion Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.